The 2024 Give to Cure Cancer Year-End Appeal is now underway. This is a chance to make this year’s campaign the most successful ever.
We are proud to report…
With support from loyal donors, excellent progress has been made in these AFCR-funded projects in the fight against cancer. Below are a few samples:
- Partnership with City University of Hong Kong (CityU): AFCR partnered with The Hong Kong Biotechnology Organization (HKBIO) and City University of Hong Kong (CityU) and organized a groundbreaking “CityU-AFCR Symposium on Precision Medicine and Digital Medicine at BIOHK2024”. This is the second annual forum of the AFCR-CityU Innovation Series in Biomedicine.
- First-in Class Molecular Glue Degraders Can Eliminate Undruggable Cancer Targets: AFCR’s support has advanced a platform of a unique and expanding library of glue compounds which alter ‘undruggable’ or difficult cancer target proteins in cells to enable their degradation and disposal in the cell. In 2024, the platform aims to obtain an Investigational New Drug application required for Phase I clinical trials and will first treat colorectal cancer patients.
- Phase IIb Clinical Trial with Botanical Drug YIV-906 Shows Promise: Research supported by AFCR since 2010 showed YIV-906 synergistically effects multiple targets in the tumor microenvironment, enhances the immune response, and alleviates gastrointestinal side effects to help patients tolerate the frontline drug. Recently completed trial sites in Hong Kong, Taiwan, Chinese mainland, and the USA treated liver cancer patients. YIV-906 has treated patients in 7 early-stage clinical trials in solid tumors (pancreatic, colorectal, and rectal cancers) with promising data suggesting that YIV-906 could prolong survival and improve quality of life.
- Novel Immunotherapy for Gastrointestinal Cancer Patients Shows Safe Results in Early Clinical Trial: The trial monitoring board recently confirmed the tolerability profile of the therapy, recommending continuation of the dose escalation of the T-cell engager therapy for patients enrolled in the Hong Kong and Australia Phase 1 trial. AFCR’s strong support facilitated development of this T-cell engager and we hope for continued positive benefits for patients enrolled in the trial.
- Revolutionary Drug Delivery Platform: Many cancer patients in dire need of treatment have other complications that limit receiving the standard of care or new leading therapies because of toxic side effects or safety concerns. AFCR supports a novel delivery system platform that dramatically improves the tolerability and efficacy of many small drugs and immunotherapeutics in models of solid tumors and blood cancers. With this innovative approach, highly active treatments can be delivered to tumors that are more tolerable for patients and easily administered.
Together, the projects could significantly improve cancer treatment and diagnosis. Your support fuels AFCR’s cutting-edge cancer research and allows us to spend the most important dollars in the fight against cancer.
Support our 2024 Give To Cure Cancer Year-End Appeal with a contribution. Please Donate Today.
The gift you give matters most. It’s likely that research discoveries being made by AFCR scientists will benefit you or someone you love in the near future.
We thank you for your continued support.
